Sarepta Therapeutics (SRPT) Total Non-Current Liabilities (2010 - 2026)

Sarepta Therapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $1.7 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 26.51% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $1.7 billion (down 26.51% YoY), while the FY2025 annual figure was $2.2 billion, down 7.56% from the prior year.
• Total Non-Current Liabilities was $1.7 billion for Q1 2026 at Sarepta Therapeutics, down from $2.2 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $2.7 billion in Q4 2022 to a low of $1.7 billion in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $2.3 billion across 5 years, with a median of $2.3 billion in 2024.
• The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities rose 25.1% in 2022, then slipped 26.51% in 2026.
• A 5-year view of Total Non-Current Liabilities shows it stood at $2.7 billion in 2022, then declined by 12.54% to $2.4 billion in 2023, then gained by 0.88% to $2.4 billion in 2024, then fell by 7.56% to $2.2 billion in 2025, then fell by 24.25% to $1.7 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $1.7 billion (Q1 2026), $2.2 billion (Q4 2025), and $2.2 billion (Q3 2025), per Business Quant data.